TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers

ABSTRACT: TNG908 is a clinical stage PRMT5 inhibitor with an MTA-cooperative binding mechanism designed to leverage the synthetic lethal interaction between PRMT5 inhibition and MTAP deletion. MTAP deletion occurs in 10–15 % of all human cancer representing multiple histologies. MTA is a negative re...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Kimberly J. Briggs, Kevin M. Cottrell, Matthew R. Tonini, Alice Tsai, Minjie Zhang, Douglas A. Whittington, Wenhai Zhang, Steven A. Lombardo, Satoshi Yoda, Erik W. Wilker, Samuel R. Meier, Yi Yu, Teng Teng, Alan Huang, John P. Maxwell
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2025-02-01
coleção:	Translational Oncology
Assuntos:	PRMT5 MTAP MTA-cooperative synthetic lethality collateral lethality
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S1936523324003905
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!